Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory to prior PD-(L)1 therapy.
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy|MSI-H Tumors
DRUG: Nivolumab|DRUG: Relatlimab|DRUG: Nivolumab|DRUG: Relatlimab|DRUG: Nivolumab|DRUG: Relatlimab
Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), 4 years
Number of participants experiencing study drug-related toxicities, 4 years
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory to prior PD-(L)1 therapy.